Zonisamide for seizures in Parkinson's disease with dementia

Tombini, Mario; Pellegrino, Giovanni; Pino, Giovanni Di; Assenza, Giovanni

doi:10.1016/j.seizure.2013.01.011

Cited by 11 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its effect on learning and memory by some studies have concluded that there is no cognitive side effect of zonisamide in low doses (200mg daily). 31,32 Our study results was similar to their study, while some study says that it has poor effect on long term use in cognition. 33,34 Results in this study conflicts from those studies.…”

Section: Zonisamide Versus Other Groups In This Studysupporting

confidence: 86%

A comparative study of effect of phenytoin, topiramate, and zonisamide in learning and memory of albino rats

Loc

Chakraborty

Kumar

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Epilepsy is one of the non-communicable neurologic diseases leading to significant morbidity and mortality. Complaints of impaired learning and memory are common in patients of epilepsy. Antiepileptic drugs (AEDs) may further enhance this impairment. So, the present study was carried out on albino rats to evaluate the effect of AEDs on learning and memory.Methods: Albino rats of about 150 -200 gm of either sex were treated with drugs for 15 days and assessed for effect on learning behavior and again treated for next 15 days after which they were assessed for retention behavior on Morris water maze and Elevated plus maze. The data was statistically analyzed by ANOVA and Tukey HSD.Results: Phenytoin and topiramate causes significant delay in learning and memory whereas zonisamide doesn’t causes significant delay in learning and memory.Conclusions: Impairment in learning and memory occurs in treatment with phenytoin and topiramate but not with zonisamide in low therapeutic doses.

show abstract

Section: Zonisamide Versus Other Groups In This Studysupporting

confidence: 86%

A comparative study of effect of phenytoin, topiramate, and zonisamide in learning and memory of albino rats

Loc

Chakraborty

Kumar

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…The highest level of evidence for zonisamide was from case series of patients with DLB (57) and PDD (58). Descriptive reports of patients with DLB (N53) suggest improvements in daily living skills, motor function, and caregiver burden in mild dementia and a reduction in psychiatric symptoms in severe dementia (57).…”

Section: Anticonvulsantsmentioning

confidence: 99%

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis

Stinton¹,

McKeith²,

Taylor³

et al. 2015

AJP

210

177

View full text Add to dashboard Cite

show abstract

“…In DLB, low doses of VPA may be effective in the treatment of agitation when combined with drugs such as quetiapine [148,149], while the GABA-ergic drug, gabapentin (GBP), may offer relief for patients with FTD [150]. Zonisamide (ZNS), a Ca 2+ channel inhibitor with broad spectrum activity, can be used in the treatment of epileptic seizures in PDD patients, while VPA should be avoided because it can worsen pyramidal symptoms [151]. In general, it seems that AEDs may prevent bouts of epilepsy and improve cognitive function in these dementias, all while displaying high tolerability and favorable pharmacokinetic profiles; however, further research into their full therapeutic effects is required.…”

Section: Pharmacotherapy Of Dementia Diseases Andmentioning

confidence: 99%

Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases

Kozubski

Ong²,

Waleszczyk

et al. 2021

Neural Plasticity

View full text Add to dashboard Cite

Neural plasticity—the ability to alter a neuronal response to environmental stimuli—is an important factor in learning and memory. Short-term synaptic plasticity and long-term synaptic plasticity, including long-term potentiation and long-term depression, are the most-characterized models of learning and memory at the molecular and cellular level. These processes are often disrupted by neurodegeneration-induced dementias. Alzheimer’s disease (AD) accounts for 50% of cases of dementia. Vascular dementia (VaD), Parkinson’s disease dementia (PDD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD) constitute much of the remaining cases. While vascular lesions are the principal cause of VaD, neurodegenerative processes have been established as etiological agents of many dementia diseases. Chief among such processes is the deposition of pathological protein aggregates in vivo including β-amyloid deposition in AD, the formation of neurofibrillary tangles in AD and FTD, and the accumulation of Lewy bodies composed of α-synuclein aggregates in DLB and PDD. The main symptoms of dementia are cognitive decline and memory and learning impairment. Nonetheless, accurate diagnoses of neurodegenerative diseases can be difficult due to overlapping clinical symptoms and the diverse locations of cortical lesions. Still, new neuroimaging and molecular biomarkers have improved clinicians’ diagnostic capabilities in the context of dementia and may lead to the development of more effective treatments. Both genetic and environmental factors may lead to the aggregation of pathological proteins and altered levels of cytokines, such that can trigger the formation of proinflammatory immunological phenotypes. This cascade of pathological changes provides fertile ground for the development of neural plasticity disorders and dementias. Available pharmacotherapy and disease-modifying therapies currently in clinical trials may modulate synaptic plasticity to mitigate the effects neuropathological changes have on cognitive function, memory, and learning. In this article, we review the neural plasticity changes seen in common neurodegenerative diseases from pathophysiological and clinical points of view and highlight potential molecular targets of disease-modifying therapies.

show abstract

Zonisamide for seizures in Parkinson's disease with dementia

Cited by 11 publications

References 17 publications

A comparative study of effect of phenytoin, topiramate, and zonisamide in learning and memory of albino rats

A comparative study of effect of phenytoin, topiramate, and zonisamide in learning and memory of albino rats

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis

Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases

Contact Info

Product

Resources

About